British Journal of Haematology最新文献_第8页

Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network. 年轻套细胞淋巴瘤患者的条件生存期：欧洲套细胞淋巴瘤网络随机III期试验结果。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-10-23 DOI: 10.1111/bjh.19854

Linmiao Jiang, Martin Dreyling, Olivier Hermine, Ulrich Mansmann, Jan Walewski, Vincent Ribrag, Catherine Thieblemont, Christiane Pott, Emmanuel Bachy, Pierre Feugier, Kai Hübel, Martin Schumacher, Eva Hoster

{"title":"Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.","authors":"Linmiao Jiang, Martin Dreyling, Olivier Hermine, Ulrich Mansmann, Jan Walewski, Vincent Ribrag, Catherine Thieblemont, Christiane Pott, Emmanuel Bachy, Pierre Feugier, Kai Hübel, Martin Schumacher, Eva Hoster","doi":"10.1111/bjh.19854","DOIUrl":"https://doi.org/10.1111/bjh.19854","url":null,"abstract":"During a fatal disease, patients often request updated information on their prognosis. After patients have already survived a certain time, conditional survival captures their future survival probability. We investigated conditional overall and failure-free survival in 473 younger mantle cell lymphoma (MCL) patients from a randomized phase III trial comparing immunochemotherapies R-CHOP and alternating R-CHOP/R-DHAP before autologous transplantation. Using conditional Kaplan-Meier method and Cox regression, we estimated subsequent survival of patients who had survived 1-8 years, considering MIPI, Ki-67, and treatment failure status. Starting at a lower level, R-CHOP patients only showed increasing subsequent survival as they survived longer (5-year conditional survival: 72% and 81% after surviving 1 and 7 years), while R-CHOP/R-DHAP patients had stable future survival over time (77% and 78%). The prognostic value of MIPI diminished after 3 years in R-CHOP patients but remained unchanged after R-CHOP/R-DHAP. Patients with treatment failure had markedly inferior survival compared with those in ongoing remission, regardless of the time survived. The longer patients remained in remission, the longer they would stay free of treatment failures. Our results enable personalized counselling for younger MCL patients by offering dynamic prognosis and underscore the importance of highly effective first-line treatment to improve survival.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142491478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A machine learning-based workflow for predicting transplant outcomes in patients with sickle cell disease. 基于机器学习的工作流程，用于预测镰状细胞病患者的移植结果。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-10-22 DOI: 10.1111/bjh.19842

Haiou Li, Vandana Sachdev, Xin Tian, My-Le Nguyen, Matthew Hsieh, Courtney Fitzhugh, Emily Limerick, Wynona Coles, Nancy Asomaning, Anna Conrey, Colin O Wu, Swee Lay Thein

引用次数: 0

Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia. 在治疗急性髓性白血病的外周血干细胞移植中，使用移植后环磷酰胺的 HLA 同源供体与 HLA 匹配的非亲缘供体的比较。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-10-22 DOI: 10.1111/bjh.19825

Makoto Moriguchi, Hirohisa Nakamae, Mitsutaka Nishimoto, Junichi Sugita, Masamitsu Yanada, Tomomi Toubai, Yuta Hasegawa, Masayuki Hino, Tetsuya Nishida, Naoki Kurita, Masashi Sawa, Takahiro Fukuda, Atsushi Jinguji, Shuichi Ota, Ken-Ichi Matsuoka, Tetsuya Eto, Nobuhiro Hiramoto, Toshihiko Ando, Koji Kawamura, Yoshinobu Kanda, Yoshiko Atsuta, Marie Ohbiki, Hideki Nakasone, Takaaki Konuma

{"title":"Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia.","authors":"Makoto Moriguchi, Hirohisa Nakamae, Mitsutaka Nishimoto, Junichi Sugita, Masamitsu Yanada, Tomomi Toubai, Yuta Hasegawa, Masayuki Hino, Tetsuya Nishida, Naoki Kurita, Masashi Sawa, Takahiro Fukuda, Atsushi Jinguji, Shuichi Ota, Ken-Ichi Matsuoka, Tetsuya Eto, Nobuhiro Hiramoto, Toshihiko Ando, Koji Kawamura, Yoshinobu Kanda, Yoshiko Atsuta, Marie Ohbiki, Hideki Nakasone, Takaaki Konuma","doi":"10.1111/bjh.19825","DOIUrl":"https://doi.org/10.1111/bjh.19825","url":null,"abstract":"HLA-haploidentical haematopoietic cell transplantation with post-transplant cyclophosphamide (PTCy-haplo) is emerging as an effective alternative due to donor availability and safety. We conducted a nationwide retrospective study comparing the outcomes of PTCy-haplo with both anti-thymocyte globulin (ATG)-free and ATG-administered matched unrelated donors (MUD) transplantation, using peripheral blood stem cells as the first transplantation for acute myeloid leukaemia (AML). Our study showed a lower and slower haematopoietic recovery and a higher incidence of infection-related deaths after PTCy-haplo than after MUD transplantation. In addition, we revealed an increased risk of acute and chronic graft-versus-host disease (GVHD) in ATG-free MUD transplantation in comparison to PTCy-haplo. For grades III-IV acute GVHD, the hazard ratio (HR) was 2.71 (95% CI, 1.46-5.01), and for extensive chronic GVHD, the HR was 3.11 (95% CI, 2.07-4.68). There was no significant difference regarding overall survival amongst the groups. In addition, GVHD-free relapse-free survival (GRFS) was lower in ATG-free MUD transplantation than in PTCy-haplo (HR, 1.46; 95% CI, 1.17-1.82). Notably, ATG-administered MUD transplantation showed no significant difference in GRFS from PTCy-haplo, negating the advantage of PTCy. Our results suggest that PTCy-haplo could be viable for AML patients without an HLA-matched related donor.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142491477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes among non-Western immigrant patients and Danish-born patients with acute myeloid Leukaemia: A Danish population-based cohort study. 非西方移民和丹麦出生的急性髓性白血病患者的预后：一项基于丹麦人口的队列研究。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-10-22 DOI: 10.1111/bjh.19850

Daniel Tuyet Kristensen, Mikkel Runason Simonsen, Anne Stidsholt Roug, Claus Werenberg Marcher, Andreas Due Ørskov, Anne Louise Tøllbøll Sørensen, Tarec Christoffer El-Galaly, Joachim Baech

引用次数: 0

Risk factors and disease trajectories of recurrent immune thrombocytopenia in children. 儿童免疫性血小板减少症复发的风险因素和疾病轨迹。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-10-22 DOI: 10.1111/bjh.19857

Yuan-Ning Yang, Li-Wen Chen, Jiann-Shiuh Chen, Yung-Chieh Lin, Yun-Hsuan Yeh, Chao-Neng Cheng

{"title":"Risk factors and disease trajectories of recurrent immune thrombocytopenia in children.","authors":"Yuan-Ning Yang, Li-Wen Chen, Jiann-Shiuh Chen, Yung-Chieh Lin, Yun-Hsuan Yeh, Chao-Neng Cheng","doi":"10.1111/bjh.19857","DOIUrl":"https://doi.org/10.1111/bjh.19857","url":null,"abstract":"This retrospective study aimed to analyse the course and outcome of recurrent immune thrombocytopenia (ITP) in children and to identify factors associated with recurrence. A total of 497 newly diagnosed ITP children with platelet <30 × 109/L between January 1988 and December 2019 were included. Recurrent ITP was defined as a new event of thrombocytopenia after at least 3 months of remission without treatment. Twenty-nine (5.8%) children experienced 48 recurrent episodes. The median time from diagnosis to recurrence was 22 months. Most recurrences occurred in children aged 1.5-10 years with a recent infection history. Compared to non-recurrent ITP, children with recurrent ITP had delayed remission with lower platelets at 1 month and 3 months postdiagnosis. Multivariate analysis identified aged 1.5-10 years (hazard ratio [HR] 3.65, 95% confidence interval [CI]: 1.35-9.82) and delayed remission at 7-12 months (HR 4.04, 95% CI: 1.37-11.95) as predictors for recurrence. Most recurrent ITP patients had minor or mild symptoms, higher platelet counts, did not require treatment, and achieved remission within 12 months. The similar remission trajectories among the first and recurrent ITP, but different from the courses in the non-recurrent ITP, suggest that recurrent ITP might have a unique biological basis.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142491487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical and genetic profiles and outcomes of allogeneic haematopoietic stem cell transplantation in secondary myelodysplastic syndrome following aplastic anaemia. 再生障碍性贫血后继发性骨髓增生异常综合征异基因造血干细胞移植的临床和遗传特征及疗效。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-10-21 DOI: 10.1111/bjh.19855

Jia Li, Runzhi Ma, Hui Wang, Yan Wang, Aiming Pang, Donglin Yang, Xin Chen, Rongli Zhang, Jialin Wei, Qiaoling Ma, Weihua Zhai, Yi He, Yizhou Zheng, Erlie Jiang, Mingzhe Han, Sizhou Feng

引用次数: 0

Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series. 阿伐曲波帕治疗化疗引起的血小板减少症患者：病例系列。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-10-21 DOI: 10.1111/bjh.19797

Robert Galamaga, Stephanie Johnston, Cassaundra Acosta

引用次数: 0

Long-term follow-up of methotrexate and cytarabine in adult patients with Langerhans cell histiocytosis. 甲氨蝶呤和阿糖胞苷对朗格汉斯细胞组织细胞增生症成年患者的长期随访。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-10-20 DOI: 10.1111/bjh.19830

He Lin, Long Chang, Min Lang, Zheng-Zheng Liu, Ming-Hui Duan, Dao-Bin Zhou, Xin-Xin Cao

{"title":"Long-term follow-up of methotrexate and cytarabine in adult patients with Langerhans cell histiocytosis.","authors":"He Lin, Long Chang, Min Lang, Zheng-Zheng Liu, Ming-Hui Duan, Dao-Bin Zhou, Xin-Xin Cao","doi":"10.1111/bjh.19830","DOIUrl":"https://doi.org/10.1111/bjh.19830","url":null,"abstract":"The optimal treatment strategy for adult Langerhans cell histiocytosis (LCH) remains unclear. Our previous study demonstrated the remarkable efficacy of combined methotrexate and cytarabine (Ara-C) [MA] therapy in patients newly diagnosed with LCH, with a median follow-up of 2 years. The present article reports long-term follow-up data spanning a median of 78 months (6.5 years) from a single-arm, single-centre, prospective phase 2 clinical trial (NCT02389400) conducted between January 2014 and December 2020. Ninety-five adults with newly diagnosed LCH exhibiting multisystem disease or multifocal single-system involvement underwent MA therapy every 35 days for six cycles. Methotrexate (1 g/m2) was administered by 24 h infusion on day 1 and AraC (0.1 g/m2) by 24 h infusion for 5 days. The primary end-point was event-free survival (EFS). The median patient age was 32 years (range 18-65 years). The overall response rate was 89.5%. Seven patients in this cohort died, and 38 experienced disease reactivation. No degenerative central nervous system diseases were observed. The estimated 6-year overall survival (OS) and EFS rates were 93.2% and 55.2% respectively. Multivariate analysis revealed that risk organ (RO) involvement at baseline (hazard ratio [HR] 6.135 [95% confidence interval (CI) 1.185-32.259]; p = 0.031) and age >40 years at diagnosis (HR 7.299 [95% CI 1.056-21.277]; p = 0.042) were associated with inferior OS. RO (HR 2.604 [95% CI 1.418-4.762]; p = 0.002) and skin (HR 2.232 [95% CI 1.171-4.255]; p = 0.015) involvement at baseline were poor prognostic factors for EFS. Regarding adverse events, four patients developed a second primary malignancy. In conclusion, the MA regimen was a valid and safe therapeutic approach for adult patients newly diagnosed with LCH.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142453991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful treatment with daratumumab for splenectomy refractory immune-mediated thrombotic thrombocytopenic purpura. 用达拉单抗成功治疗脾切除术难治性免疫介导的血栓性血小板减少性紫癜。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-10-20 DOI: 10.1111/bjh.19856

A J Gerard Jansen, Minke A E Rab, Peter A W Te Boekhorst, Frank W G Leebeek

引用次数: 0

Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma. 各种移植平台的疗效比较，重点是单倍体移植和移植后环磷酰胺治疗成人T细胞白血病/淋巴瘤。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-10-19 DOI: 10.1111/bjh.19835

Makoto Yoshimitsu, Takashi Tanaka, Nobuaki Nakano, Koji Kato, Hiroyuki Muranushi, Masahito Tokunaga, Ayumu Ito, Jun Ishikawa, Tetsuya Eto, Satoko Morishima, Toshiro Kawakita, Hidehiro Itonaga, Naoyuki Uchida, Masatsugu Tanaka, Keiichi Akizuki, Kenji Ishitsuka, Hiroyuki Ohigashi, Shuichi Ota, Toshihiko Ando, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Shigeo Fuji

{"title":"Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma.","authors":"Makoto Yoshimitsu, Takashi Tanaka, Nobuaki Nakano, Koji Kato, Hiroyuki Muranushi, Masahito Tokunaga, Ayumu Ito, Jun Ishikawa, Tetsuya Eto, Satoko Morishima, Toshiro Kawakita, Hidehiro Itonaga, Naoyuki Uchida, Masatsugu Tanaka, Keiichi Akizuki, Kenji Ishitsuka, Hiroyuki Ohigashi, Shuichi Ota, Toshihiko Ando, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Shigeo Fuji","doi":"10.1111/bjh.19835","DOIUrl":"https://doi.org/10.1111/bjh.19835","url":null,"abstract":"This study retrospectively compared outcomes of various allogeneic haematopoietic cell transplantation (allo-HCT) platforms in patients with adult T-cell leukaemia/lymphoma. Platforms included human leukocyte antigen (HLA)-haploidentical-related donors using post-transplant cyclophosphamide (PTCY), HLA-matched related donors (MRD), HLA-matched unrelated donors (MUD) and cord blood transplantation (CBT). Patients who underwent their first allo-HCT between 2016 and 2021 were included. Outcomes analysed were overall survival (OS), relapse and non-relapse mortality (NRM). Seven hundred patients were included (PTCY, n = 121; MRD, n = 91; MUD, n = 160; CBT, n = 328). With a median follow-up of 794 days for survivors, 2-year OS was 48.1% (PTCY), 48.8% (MRD), 48.4% (MUD) and 34.6% (CBT); the respective 2-year cumulative incidence of relapse was 37.1%, 47.5%, 33.9% and 45.1% and that of NRM was 24.2%, 19.8%, 24.7% and 27.3%. PTCY was associated with delayed platelet engraftment relative to MRD and MUD. There was no increase in the incidence of severe acute or chronic graft-versus-host disease. In the PTCY group, poor performance status was a significant predictor of inferior OS, and infused CD34+ cell numbers of less than 5 × 106/kg were associated with delayed neutrophil and platelet engraftment. These results suggest that allo-HCT with PTCY is a safe and effective platform for patients with adult T-cell leukaemia/lymphoma.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142453987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0